Get the Stockscreener App
9.98
2.15%
0.21
Niagen Bioscience Inc stock is traded at $9.98, with a volume of 857.66K.
It is up +2.15% in the last 24 hours and up +5.61% over the past month.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
See More
Previous Close:
$9.77
Open:
$9.94
24h Volume:
857.66K
Relative Volume:
0.79
Market Cap:
$795.93M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.40%
1M Performance:
+5.61%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.72
$10.14
1-Week Range:
$9.37
$10.45
52-Week Range:
$5.33
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Name
Niagen Bioscience Inc
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
9.98 | 807.10M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Canaccord Genuity | Buy |
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Niagen Bioscience Inc Stock (NAGE) Latest News
While Shareholders of Niagen Bioscience (NASDAQ:NAGE) Are in the Black Over 3 Years, Those Who Bought a Week Ago Aren't so Fortunate - 富途牛牛
Q3 EPS Forecast for Niagen Bioscience Decreased by Analyst - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat
Niagen Bioscience's Q2 2025 Earnings: A Catalyst for NAD+ Market Leadership and Long-Term Value Creation - AInvest
Niagen Bioscience, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NAGE) - Seeking Alpha
Quant Models Detect Momentum Reversal in Niagen Bioscience Inc.Stock Surge & Daily Oversold Stock Bounce Ideas - 선데이타임즈
Q2 EPS Estimate for Niagen Bioscience Boosted by Analyst - MarketBeat
Niagen Bioscience Shares Climb Following Exclusive License for Parkinson’s Therapy - MSN
Is Niagen Bioscience Inc. forming a bullish divergenceWeekly Profit Recap & Proven Capital Preservation Tips - mustnews.co.kr
Is Niagen Bioscience Inc. a defensive stockJuly 2025 Big Picture & Momentum Based Trading Signals - thegnnews.com
RSI Divergence May Trigger a Bounce in Niagen Bioscience Inc.New Guidance & Verified Chart Pattern Signals - newsimpact.co.kr
Is Niagen Bioscience Inc. forming higher highs and higher lowsMarket Activity Summary & AI Powered Market Trend Analysis - thegnnews.com
Bullish Candlestick Pattern Forms in Niagen Bioscience Inc.2025 Year in Review & Free Fast Gain Swing Trade Alerts - metal.it
HC Wainwright Issues Positive Forecast for Niagen Bioscience (NASDAQ:NAGE) Stock Price - MarketBeat
Niagen Bioscience Inc. Stock Approaches Key Moving Average2025 Earnings Surprises & AI Powered Buy/Sell Recommendations - 선데이타임즈
Q2 EPS Estimate for Niagen Bioscience Increased by Analyst - MarketBeat
Niagen: Imminent Trigger For A Significant Move Up (Technical Analysis) - Seeking Alpha
Quince, Niagen, Intrabio busy in rare A-T disease - BioWorld MedTech
Promising Growth and Innovation Drive Buy Rating for Niagen Bioscience - TipRanks
Equities Analysts Offer Predictions for NAGE Q3 Earnings - MarketBeat
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives $13.22 Average PT from Brokerages - MarketBeat
Momentum Screeners Rank Niagen Bioscience Inc. in Top 5 TodayConsistent Income Focused Trade List Analyzed - beatles.ru
Niagen Bioscience stock price target raised to $12 from $11 at H.C. Wainwright - Investing.com Canada
Real time scanner hits for Niagen Bioscience Inc. explainedRisk Balanced Picks for Safer Trading - Newser
Niagen Bioscience Reports Strong Q2 Growth and Outlook - TipRanks
News impact scoring models applied to Niagen Bioscience Inc.In-Depth Stock Trading Volume Analysis - Newser
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up Following Earnings Beat - MarketBeat
Risk adjusted return profile for Niagen Bioscience Inc. analyzedSafe and Scalable Return Strategy Blueprint - Newser
Can Niagen Bioscience Inc. rally from current levelsLow Risk Strategy with Smart Entry Zones - Newser
Roth Capital Cuts Earnings Estimates for Niagen Bioscience - Defense World
Will a bounce in Niagen Bioscience Inc. offer an exitProven Trading System with Consistent Gains - Newser
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Should you wait for a breakout in Niagen Bioscience Inc.Free Fundamental Growth Stock Analysis - Newser
Niagen Bioscience Reports Strong Q2 Sales Growth - The Globe and Mail
Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates - MSN
Niagen Bioscience: Q2 Earnings Snapshot - New Haven Register
Niagen Bioscience (NASDAQ:NAGE) Cut to Buy at Wall Street Zen - MarketBeat
Niagen Bioscience shares rise 21.91% premarket after Q2 sales beat estimates. - AInvest
Earnings call transcript: Niagen Bioscience Q2 2025 earnings beat expectations - Investing.com
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook - BioSpace
Niagen NAGE Q2 2025 Earnings Call Transcript - Mitrade
Niagen Bioscience shares rise 24.88% after-hours after Q2 sales beat estimates. - AInvest
Transcript : Niagen Bioscience, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Niagen Bioscience Inc Stock (NAGE) Financials Data
There is no financial data for Niagen Bioscience Inc (NAGE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Niagen Bioscience Inc Stock (NAGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):